From a Cone Snail Toxin to a Competitive MC4R Antagonist.

The melanocortin 4 receptor (MC4R) plays a role in energy homeostasis and represents a target for treating energy balance disorders. For decades, synthetic ligands have been derived from MC4R endogenous agonists and antagonists, such as setmelanotide used to treat rare forms of genetic obesity. Recently, animal venoms have demonstrated their capacity to provide melanocortin ligands with toxins from a scorpion and a spider. Here, we described a cone snail toxin, N-CTX-Ltg1a, with a nanomolar affinity for hMC4R but unrelated to any known toxins or melanocortin ligands. We then derived from the conotoxin the linear peptide HT1-0, a competitive antagonist of Gs, G15, and β-arrestin2 pathways with a low nanomolar affinity for hMC4R. Similar to endogenous ligands, HT1-0 needs hydrophobic and basic residues to bind hMC4R. Altogether, it represents the first venom-derived peptide of high affinity on MC4R and paves the way for the development of new MC4R antagonists.

• Publication year

  2022

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2022-09-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.2c00786PMID 36063022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically relevant GPCRs

  2022cited by this paper
• Structural and Functional Diversity of Animal Toxins Interacting With GPCRs

  2022cited by this paper
• Setmelanotide: First Approval

  2021cited by this paper
• Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide

  2021cited by this paper
• The melanocortin pathway and energy homeostasis: From discovery to obesity therapy

  2021cited by this paper
• APPTEST is a novel protocol for the automatic prediction of peptide tertiary structures

  2021cited by this paper
• Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs

  2021cited by this paper
• Human MC4R variants affect endocytosis, trafficking and dimerization revealing multiple cellular mechanisms involved in weight regulation

  2021cited by this paper
• A Venomics approach coupled to high-throughput toxin production strategies identifies the first venom-derived melanocortin receptor agonists.

  2020cited by this paper
• Determination of the melanocortin-4 receptor structure identifies Ca2+ as a cofactor for ligand binding

  2020cited by this paper
• Structure–Activity Relationships of the Tetrapeptide Ac-His-Arg-(pI)DPhe-Tic-NH2 at the Mouse Melanocortin Receptors: Modification at the (pI)DPhe Position Leads to mMC3R Versus mMC4R Selective Ligands

  2019cited by this paper
• Translating biased signaling in the ghrelin receptor system into differential in vivo functions

  2018cited by this paper
• Synergistic Multiresidue Substitutions of a Macrocyclic c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-dPro] Agouti-Related Protein (AGRP) Scaffold Yield Potent and >600-Fold MC4R versus MC3R Selective Melanocortin Receptor Antagonists.

  2018cited by this paper
• Arg-Phe-Phe d-Amino Acid Stereochemistry Scan in the Macrocyclic Agouti-Related Protein Antagonist Scaffold c[Pro-Arg-Phe-Phe-Xxx-Ala-Phe-DPro] Results in Unanticipated Melanocortin-1 Receptor Agonist Profiles.

  2018cited by this paper
• Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice.

  2018cited by this paper
• MC4R Agonists: Structural Overview on Antiobesity Therapeutics.

  2018cited by this paper
• Melanocortin Receptor 4 Signaling Regulates Vertebrate Limb Regeneration.

  2018cited by this paper
• Structure-Activity Relationship Studies on a Macrocyclic Agouti-Related Protein (AGRP) Scaffold Reveal Agouti Signaling Protein (ASP) Residue Substitutions Maintain Melanocortin-4 Receptor Antagonist Potency and Result in Inverse Agonist Pharmacology at the Melanocortin-5 Receptor.

  2017cited by this paper
• A new inhibitor of the β-arrestin/AP2 endocytic complex reveals interplay between GPCR internalization and signalling

  2017cited by this paper
• Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease

  2017cited by this paper
• Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET

  2016cited by this paper
• The Role of the Melanocortin System in Metabolic Disease: New Developments and Advances

  2016cited by this paper
• A neural basis for melanocortin-4 receptor regulated appetite

  2015cited by this paper
• RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.

  2015cited by this paper
• G(q/11)α and G(s)α mediate distinct physiological responses to central melanocortins.

  2015cited by this paper
• Discovery of a β-Hairpin Octapeptide, c[Pro-Arg-Phe-Phe-Dap-Ala-Phe-DPro], Mimetic of Agouti-Related Protein(87-132) [AGRP(87-132)] with Equipotent Mouse Melanocortin-4 Receptor (mMC4R) Antagonist Pharmacology.

  2015cited by this paper
• Discovery, synthesis, and structure-activity relationships of conotoxins.

  2014cited by this paper
• The European FP7 Venomics Project.

  2014cited by this paper
• Development and Characterization of Pepducins as Gs-biased Allosteric Agonists*♦

  2014cited by this paper
• High-throughput production of two disulphide-bridge toxins.

  2014cited by this paper
• G-protein independent coupling of the MC4R to Kir 7.1 in hypothalamic neurons

  2014cited by this paper
• The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

  2014cited by this paper
• Molecular and functional analysis of human β-defensin 3 action at melanocortin receptors.

  2013cited by this paper
• Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein

  2013cited by this paper
• Structure-activity relationships (SAR) of melanocortin and agouti-related (AGRP) peptides.

  2010cited by this paper
• The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.

  2010cited by this paper
• Pertussis Toxin-sensitive Signaling of Melanocortin-4 Receptors in Hypothalamic GT1-7 Cells Defines Agouti-related Protein as a Biased Agonist*

  2009cited by this paper
• A rational nomenclature for naming peptide toxins from spiders and other venomous animals.

  2008cited by this paper
• Activation of the melanocortin-4 receptor mobilizes intracellular free calcium in immortalized hypothalamic neurons.

  2006cited by this paper
• A novel conotoxin framework with a helix-loop-helix (Cs α/α) fold

  2005cited by this paper
• A novel conotoxin framework with a helix-loop-helix (Cs alpha/alpha) fold.

  2005cited by this paper
• Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.

  2004cited by this paper
• Molecular determination of agouti-related protein binding to human melanocortin-4 receptor.

  2003cited by this paper
• Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene.

  2003cited by this paper
• Molecular determinants of ligand binding to the human melanocortin-4 receptor.

  2000cited by this paper
• Molecular interaction of Agouti protein and Agouti-related protein with human melanocortin receptors.

  1999cited by this paper
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

  1999cited by this paper
• Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors.

  1995cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Natural Peptide Toxins as an Option for Renewed Treatment of Type 2 Vasopressin Receptor-Related Diseases

  2023cites this paper